The Journal of Practical Medicine >

2023 , Vol. 39 >Issue 19: 2495 - 2500

DOI: https://doi.org/10.3969/j.issn.1006-5725.2023.19.014

Clinical Research

Diagnostic and Prognostic Value of HDAC4 and Fibrinogen/Albumin Ratio in Non⁃small Cell Lung Cancer

  • Jie ZHANG ,
  • Fanliang. MENG
Expand
  • Department of Respiratory Diseases，Chaohu Hospital，Anhui Medical University，Chaohu 238000，China

Received date: 2023-06-12

  Online published: 2023-11-22

Fold

Abstract

Objective To analyze the levels and prognostic value of histone deacetylase 4 （HDAC4） and the fibrinogen/albumin ratio （FAR） in the circulation of patients with non?small cell lung cancer（NSCLC） as well as the diagnostic value of these two factors combined. Methods The enzyme?linked immunosorbent assay was applied to determine the serum HDAC4 levels and detect the levels of fibrinogen， albumin， and carcinoembryonic antigen in 117 patients with NSCLC （lung cancer group）， 50 patients with benign lung disease （reference group）， and 50 healthy subjects （healthy control group）. The HDAC4 and FAR levels were compared within the three groups. The associations of HDAC4 and FAR with the clinical features and the diagnostic and prognostic value of the two factors combined in NSCLC were analyzed. Results The levels of FAR and serum HDAC4 were significantly higher in the circulation of the NSCLC group compared with the reference and control groups （P < 0.05）. HDAC4 and FAR were positively correlated with TNM stage， tumor size， lymph node metastasis， and distant metastasis （P < 0.05）. HDAC4 combined with FAR had an AUC of 0.782， sensitivity of 59%， and specificity of 96% in non?small cell diagnosis. Survival analysis showed that higher HDAC4， FAR predicted shorter progression?free survival （PFS） （log?rank test， P < 0.05）. Multifactorial analysis showed that HDAC4， FAR， distant metastasis， and treatment regimen were independent risk factors affecting the prognosis （PFS） of patients with non?small cell lung cancer （P < 0.05）. Conclusions HDAC4 and FAR levels are elevated in the circulation of NSCLC patients， and the combination of HDAC4 and FAR has good clinical reference value for lung cancer diagnosis. Moreover， higher levels of HDAC4 and FAR are associated with poorer prognosis in NSCLC patients， suggesting their potential as prognostic indicators for evaluating the prognosis of NSCLC patients.

Key words： HDAC4; fibrinogen/albumin ratio; non?small cell lung cancer; diagnosis; prognosis

Cite this article

Jie ZHANG , Fanliang. MENG . Diagnostic and Prognostic Value of HDAC4 and Fibrinogen/Albumin Ratio in Non⁃small Cell Lung Cancer[J]. The Journal of Practical Medicine, 2023 , 39(19) : 2495 -2500 . DOI: 10.3969/j.issn.1006-5725.2023.19.014

References

1 SUNG H， FERLAY J， SIEGEL R L， et al. Global cancer statistics 2020： GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin， 2021， 71（3）： 209-249.
2 NASIM F， SABATH B F， EAPEN G A. Lung Cancer［J］. Med Clin North Am，2019，103（3）：463?473.
3 CUTTINI E， GOI C， PELLARIN E， et al. HDAC4 in cancer： A multitasking platform to drive not only epigenetic modifications［J］. Front Mol Biosci， 2023， 10： 1116660.
4 PERUZZO P， COMELLI M， DI GIORGIO E， et al. Transformation by different oncogenes relies on specific metabolic adaptations［J］. Cell Cycle， 2016， 15（19）： 2656-2668.
5 WANG T， LU Z， HAN T， et al. Deacetylation of glutaminase by HDAC4 contributes to lung cancer tumorigenesis［J］. Int J Biol Sci， 2022， 18（11）： 4452-4465.
6 CHENG C， YANG J， LI S W， et al. HDAC4 promotes nasopharyngeal carcinoma progression and serves as a therapeutic target［J］. Cell Death Dis， 2021， 12（2）： 137.
7 ZANG W J， HU Y L， QIAN C Y， et al. HDAC4 promotes the growth and metastasis of gastric cancer via autophagic degradation of MEKK3［J］. Br J Cancer， 2022， 127（2）： 237-248.
8 CAI J Y， XU T T， WANG Y， et al. Histone deacetylase HDAC4 promotes the proliferation and invasion of glioma cells［J］. Int J Oncol， 2018， 53（6）： 2758-2768.
9 ZeNG L S， YANG X Z， WEN Y F， et al. Overexpressed HDAC4 is associated with poor survival and promotes tumor progression in esophageal carcinoma［J］. Aging （Albany NY）， 2016， 8（6）： 1236.
10 薄维波，秦继宝，陈隽，等. 血清异常凝血酶原在中晚期肝癌患者中的表达及预后［J］. 实用医学杂志，2021，37（23）：3036-3040.
11 李生平，周业江. 手术前后白蛋白与球蛋白比值变化对结肠癌预后的评估价值［J］. 实用医学杂志，2019，35（5）：783-788.
12 JONES J M， MCGONIGLE N C， MCANESPIE M， et al. Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer［J］. Lung Cancer， 2006， 53（1）： 97-101.
13 MORANO M T A P， MESQUITA R， SILVA G P F DA， et al. Comparison of the effects of pulmonary rehabilitation with chest physical therapy on the levels of fibrinogen and albumin in patients with lung cancer awaiting lung resection： a randomized clinical trial［J］. BMC Pulmonary Med， 2014， 14： 1-7.
14 HOU F， WEI W， QIN X， et al. The posttranslational modification of HDAC4 in cell biology： mechanisms and potential targets［J］. J Cell Biochem， 2020， 121（2）： 930-937.
15 LI Y， WANG K， WEI Y， et al. lncRNA-MIAT regulates cell biological behaviors in gastric cancer through a mechanism involving the miR-29a-3p/HDAC4 axis［J］. Oncol Rep， 2017， 38（6）： 3465-3472.
16 WANG H， LI C， JIAN Z， et al. TGF-β1 reduces miR-29a expression to promote tumorigenicity and metastasis of cholangiocarcinoma by targeting HDAC4［J］. PLoS One， 2015， 10（10）： e0136703.
17 WU G， YU W， ZHANG M， et al. MicroRNA-145-3p suppresses proliferation and promotes apotosis and autophagy of osteosarcoma cell by targeting HDAC4［J］. Artif Cells Nanomed Biotechnol， 2018， 46（sup2）： 579-586.
18 SUN Y， QIN B. Long noncoding RNA MALAT1 regulates HDAC4‐mediated proliferation and apoptosis via decoying of miR‐140‐5p in osteosarcoma cells［J］. Cancer Med， 2018， 7（9）： 4584-4597.
19 ZHAO J， ZHAO M， JIN B， et al. Tumor response and survival in patients with advanced non-small-cell lung cancer： the predictive value of chemotherapy-induced changes in fibrinogen［J］. BMC Cancer， 2012， 12： 1-9.
20 IM J H， FU W， WANG H， et al. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation［J］. Cancer Res， 2004， 64（23）： 8613-8619.
21 ZHENG S， JIA Y， ZHAO J U N， et al. Ganoderma lucidum polysaccharides eradicates the blocking effect of fibrinogen on NK cytotoxicity against melanoma cells［J］. Oncol Lett， 2012， 3（3）： 613-616.
22 GUPTA D， LIS C G. Pretreatment serum albumin as a predictor of cancer survival： a systematic review of the epidemiological literature［J］. Nutr J， 2010， 9（1）： 1-16.
23 ASHER V， LEE J， BALI A. Preoperative serum albumin is an independent prognostic predictor of survival in ovarian cancer［J］. Med Oncol， 2012， 29： 2005-2009.
24 ZITVOGEL L， PIETROCOLA F， KROEMER G. Nutrition， inflammation and cancer［J］. Nat Immunol， 2017， 18（8）： 843-850.
25 江承川，李茉莉，刘莎，等. 不同剂量调强放疗联合同步化疗对局部晚期肺癌患者生存期和毒副反应的影响［J］. 中国医学物理学杂志， 2022，39（11）：1345-1348.
26 WENG J， HUANG J， YU W， et al. Combination of albumin concentration and neutrophil-to-lymphocyte ratio for predicting overall survival of patients with non-small cell lung cancer［J］. J Thorac Dis， 2021， 13（9）： 5508-5516.
Options
Outlines

/

〈 〉